Markets

Israeli ADHD drug developer Alcobra sets terms for $15 million IPO

An image of a person holding up a graph
Credit: Shutterstock photo

Alcobra, an Israeli biopharmaceutical company focused on the development of a drug to treat ADHD, announced terms for its IPO on Tuesday. The Tel Aviv, Israel-based company plans to raise $15 million by offering 1.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Alcobra would command a fully diluted market value of $102 million. Alcobra, which was founded in 2008 and is yet to generate any revenue, plans to list on the NASDAQ under the symbol ADHD. . Aegis Capital is the sole underwriter on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More